Your patients are resilient.

Their valves should be too.

Discover how RESILIA tissue is enabling the latest class of resilient heart valves

Edwards

Today's patient:
Needs and expectations

Your patients are living longer than ever before – and they want to live their longer lives to the fullest, continuing to enjoy their active lifestyles.

Current technology:
Inherent limitations

The primary mode of failure for bovine pericardial valves is calcification.



Patients in the future may need a more resilient tissue solution

Making tissue more resilient:
Introducing RESILIA tissue

RESILIA tissue is bovine pericardial tissue transformed by the addition of a novel **integrity preservation technology**, which incorporates two proprietary features.





1 Stable-capping permanently blocks free aldehydes



Integrity preservation technology
virtually eliminates free aldehydes while protecting and preserving the tissue

2 Glycerolization prevents further exposure
to aldehydes



No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.

The path to the latest class of tissue valves:
A rigorous 13-year development program

RESILIA tissue has been subjected to **over 100 evaluations of safety and efficacy**.



Preclinical evaluation:
Valves with RESILIA tissue

Valves with RESILIA tissue were compared against PERIMOUNT valves in a large, first-of-its-kind juvenile sheep study.[2]



Mitral valve is **worst case for calcification** in sheep

Maximum duration before sheep outgrow valve, and **more than the 5-month duration required by regulatory agencies**

Blinded assessment & analysis – **reduced risk of bias**

This model mirrors the accelerated calcification that is often seen in younger humans.[2]

* Carpentier-Edwards PERIMOUNT Plus pericardial mitral bioprosthesis, model 6900P.
No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.

Preclinical evaluation:
Valves with RESILIA tissue

Significant reduction in leaflet calcification and improved sustained hemodynamic performance.

Calcium content[2]



Horizontal lines represent mean; boxes represent mean ± standard error; whiskers represent mean ± 0.95 confidence interval

Mean gradient[2]



Whiskers represent mean ± standard error of the mean

* Carpentier-Edwards PERIMOUNT Plus pericardial mitral bioprosthesis, model 6900P.
No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.

Clinical evaluation:
Valves with RESILIA tissue

Over 800 patients have received a valve with RESILIA tissue in the aortic position.



Refer to clinicaltrials.gov for additional information: 1. Aortic: NCT01757665 2. Aortic: NCT01651052
Device using RESILIA tissue is commercially available in the EU for the aortic position only.

RESILIA tissue is enabling the latest class of resilient heart valves



RESILIA tissue valves are the first and only class of valves to deliver the combination of:

1. **Improved anti-calcification properties***
2. **Improved sustained hemodynamic performance***
3. **Unique preservation for dry storage**

* RESILIA tissue tested against commercially-available bovine pericardial tissue from Edwards in a juvenile sheep model.[2]

Discover how RESILIA tissue is enabling the latest class of resilient heart valves

What is RESILIA tissue?

RESILIA tissue is bovine pericardial tissue transformed by a novel integrity preservation technology.

What makes RESILIA tissue different?

Integrity preservation technology incorporates two proprietary features that, together, virtually **eliminate free aldehydes** while protecting and preserving the tissue.



What defines a RESILIA tissue valve?

RESILIA tissue valves comprise the latest class of resilient bovine pericardial heart valves, the first to deliver the combination of:

Improved anti-calcification properties*

Improved sustained hemodynamic performance*

Unique preservation for dry storage

* RESILIA tissue tested against commercially-available bovine pericardial tissue from Edwards in a juvenile sheep model.[2] No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.

Reference

1. World Health Organization. World Health Statistics 2014. Geneva, Switzerland: WHO; 2014. WHO/HIS/HSI/14.1.
2. Flameng W, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. *J Thorac Cardiovasc Surg.* 2015;149:340–5.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Important Safety Information pertaining to valves manufactured with RESILIA tissue is available on the device-specific brochure.

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com

Edwards